• Las Vegas-based jewelry maker GEMXX Corporation is reporting positive net revenues, and $0.00 in long-term liabilities, in the company’s recently released quarterly financial statement
• GEMXX is unique in that it mines its own gold resources and is making plans to operate the world’s largest Ammolite gemstone mine soon, all for its distinctively iridescent jewelry products
• Ammolite is a gemstone derived from the fossilized shells of large, extinct marine nautiluses — commercially mined in Alberta, Canada, and nowhere else in the world
• The company has a fully qualified Tier 1, Form 1A registration to raise up to $6 million through its Reg-A offering

Mine-to-market jewelry innovator GEMXX (OTC: GEMZ) continues to build a strong gold and gemstone supply chain based on its Canadian land resources and sound financial asset management, as noted in the company’s recent quarterly financial statement.

“We have made considerable strides in the past year and continue to post positive net revenues,” GEMXX CEO Jay Maull stated in the company’s news release (https://ibn.fm/pHm1R). “We have also reduced our total long-term liabilities to $0.00, which is a remarkable achievement. One that tangibly reinforces our ambitious commitment to building strategic partnerships, the pursuit of smart growth and expansion plans, introduction of new complementary product lines, and our focus on increasing shareholder value.”

GEMXX is notable as a company that mines its own gold reserves for use in its jewelry production as well as being the only publicly traded Ammolite mining company in the world, which provides GEMXX the ability to control every aspect of its production process and keep its prices competitive.

GEMXX has two gold resources in British Columbia — the 498-acre Snow Creek Mine and the 240-acre Rosella Creek project, which have estimated production potential of over 100,000 ounces of easily recoverable gold, according to initial testing at the sites (https://ibn.fm/in0qC).

In Alberta, the company continues to manage its Ammolite sources to produce the iridescent and distinctive gemstone derived from the fossilized shells of ammonites, a group of large, extinct marine nautiluses.

Alberta is the only place the rare gemstone is commercially mined and GEMXX works with world-class gem cutters and jewelry designers to deliver distinctive products that are delivered to customers around the world.

The company’s quarterly report shows that net income remains positive at $46,279 and account receivables increased to just over $1 million. GEMXX’s total assets have grown to $19.3 million.

GEMXX is partnering with Crazy Horse Mining Inc. to develop its gold assets to supply its global operation and reported the production of its first gold extraction at the Snow Creek Mine site this past month. The initial results have met or exceeded all expectations.

With no long-term debt, GEMXX plans to grow its market share by expanding its supplier relationships, opening new targeted markets and acquiring competitors.

“Upon completion of the S-K 1300 Reports on the company’s Southern Blocks, Management forecasts the NPV of the company’s assets to increase at least three-fold (3X). This is an exciting opportunity to become an investor in a rare product with increasing demand, and a company dedicated to growing across multiple markets, owning every step of production,” the company’s marketing materials state (https://ibn.fm/hgsAA).

The company has a fully qualified Regulation A offering to raise up to $6 million in investment through a Reg-A offering. Those interested in participating through Reg A financing are encouraged to visit the company’s investor page (https://ibn.fm/Hqpre) or contact the company officials for more information (ir@gemxx.com – 702-930-1815).

For more information, visit the company’s website at www.GEMXX.com.

NOTE TO INVESTORS: The latest news and updates relating to GEMZ are available in the company’s newsroom at https://ibn.fm/GEMZ

Industry experts, entrepreneurs, investors, and innovators from all areas of the medical industry are invited to attend the Octanes Medical Innovation Forum 2023 being held October 25-26, 2023, at the Irvine Marriott, Irvine, California. The two-day event is set to present a convergence of revolutionary technologies, advanced ideas, and the best industry expertise. Leveraging the transformative power of entrepreneurial intelligence, the event is dedicated to promoting a culture of innovation within the medical industry.

The Octane’s Medical Innovation Forum 2023 will bring together luminaries, industry veterans, and disruptive startups, to explore innovations on the edge of medical transformation. As the healthcare landscape evolves at an unparalleled pace, the Octanes Medical Innovation Forum 2023 is poised to provide invaluable insights and expedite dynamic collaborations that will shape the future of healthcare.

Promoting a Culture of Innovation

The Octane’s Medical Innovation Forum 2023 serves as a dynamic platform where established businesses and startups will learn about groundbreaking technologies and the latest advancements. One of the key benefits of the event is the unique gathering of visionaries and medical experts. The thought leaders will share insights into the evolving healthcare landscape. This immersive experience will offer attendees a firsthand perspective towards the improvements representing groundbreaking intelligence.

The Forum offers a great opportunity for attendees to be inspired and enlightened by a diverse spectrum of expertise. Expert-led sessions are specially designed to provoke thought, foster dialogue, and inspire innovative solutions. Attendees will gain valuable insights into the trending topics including the integration of AI in healthcare, the evolving funding environment, the role of hospitals with innovative product development, and much more.

For additional information, please visit https://ibn.fm/bBXyE.

• SenesTech Inc. is building worldwide influence as a rat population control solution that humanely and cost-effectively based on fertility control
• The company’s trademarked ContraPest(R) brand is designed to target rat pest populations large and small, as well as hard-to-get roof rodents, and is the only EPA-registered rat contraception product for both male and female rats
• The rebound in rat populations worldwide in the wake of the COVID pandemic and a recent report on the spread of the rat lungworm parasite (which can sicken or kill humans) have fostered a new sense of concern about rat-carried diseases
• SenesTech is expanding its international presence, with new client agreements this summer in The Maldives and South Africa. Additional discussions are underway in South America and Asia

Controlling rat populations and the diseases associated with them has been a concern for centuries, underlined in the public consciousness by historical plagues believed to be spread by rats, including the 14th century “Black Death” that remains the most fatal pandemic recorded in human history, causing the deaths of 75–200 million people (https://ibn.fm/DdhRa).

In the modern era, rat populations are rebounding in the wake of the COVID pandemic (https://ibn.fm/w8w6y) and in tandem with global climate change (https://ibn.fm/ldHpL), leading afflicted municipal authorities to seek creative solutions for coping with them. Some have proved humorous — Paris’ mayor recently drew snickers for rewriting its “anti-rat plan” with the establishment of a rat-coexistence “committee on the question of cohabitation” (https://ibn.fm/HLSH3), while New Yorkers are drawing attention to their pestilence through a booming new “rat tourism” market (https://ibn.fm/BZADj) for people who cheer the rodents’ squeaks and squeals.

But the potential for deadly and debilitating diseases spread by rats remains a worry for the general population. A small study describing the advancing spread of rat lungworm, a parasite that can ultimately infect humans, into a new area of the southeastern United States (https://ibn.fm/Uf9xs) spawned news media headlines this past month such as “Worm that jumps from rats to slugs to human brains has invaded Southeast US” (https://ibn.fm/9AUDE).

Rodent control innovator SenesTech (NASDAQ: SNES) is spreading its clean-cities solution for stopping the growth of rat populations through agreements with government and industry partners around the world, which in recent months have included officials in Washington and California (https://ibn.fm/yh7hg), the Maldives (https://ibn.fm/zOOV0) and South Africa (https://ibn.fm/FnPEs).

SenesTech’s trademarked ContraPest(R) brand has the distinction of being the only EPA-registered birth control for male and female rats, which simply limits the enormous (tens of thousands per year) pupping rate of the rodents. The company serves governmental integrated pest management (“IPM”) programs as well as individual customers seeking smaller-scale solutions.

ContraPest has been shown to reduce rat activity over 90 percent in IPM programs (https://ibn.fm/PnVr4), with varied formulations designed to target problem areas based on size and location (such as if an above-ground, roof area solution is needed).

The costs of rat infestation can be enormous for afflicted businesses. One poultry farm reported losing up to $500,000 per year just in feed taken by rodents it had failed to control despite varied efforts. After the Florida company was introduced to Contra Pest, it reported reduced feed loss and an 88 percent recovery from pullet loss due to predation (https://ibn.fm/DFjxV).

“When we introduced ContraPest, we needed to convince the pest control market of two things: the value of fertility control, and the applicability of a liquid bait into their procedures,” SenesTech President and CEO Joel Fruendt stated in a July news release (https://ibn.fm/F4JiY). “With continued revenue growth, new product introductions, expanded sales and distribution agreements, and a keen focus on operational improvements to drive the business towards profitability, I believe we made good progress over the past quarter. With 126% sales growth during the month of July 2023, I believe we are well positioned for a strong second half of the year.”

For more information, visit the company’s website at www.SenesTech.com.

NOTE TO INVESTORS: The latest news and updates relating to SNES are available in the company’s newsroom at https://ibn.fm/SNES

• SOHM just announced the appointment of Wm. Dewey Rushing as the new VP-Quality
• His appointment follows the recent nomination of Dr. Krishna Bhat as the new Chief Medical Advisor and Dr. David Aguilar as the new COO
• It also follows the recently signed LOI for SOHM to acquire ABBIE stem cell disruptive technology and patents from CGA Intellectual Holdings Inc.

SOHM (OTC: SHMN), a generic drug manufacturing and distributing innovator, is bolstering its executive team as it eyes the global nutraceuticals market, which is expected to post a CAGR of 9.4% between 2023 and 2030, and the global NSAID market which is also expected to be valued at $30 billion by 2030. SOHM’s strategic approach has seen it bring experts on board, some of whom have previously served in advisory capacities within the company and have a good understanding of its ethos, vision, and overall approach to solving client problems.

On September 11, the company announced the appointment of Wm. Dewey Rushing as the new Vice President-Quality. Mr. Rushing previously served as an Advisory Board member at the company since 2022. His years of experience in cell therapy IND readiness, quality systems audits, aseptic processing, and cGMP compliance and regulation make him a valuable asset to the company, mainly as it explores the next steps for growth (https://ibn.fm/YQ86u).

While announcing his appointment, Baron Night, SOHM’s President and CEO, lauded Mr. Rushing’s value to the company, noting how instrumental he has been in providing his expertise on validation and compliance issues.

“SOHM has appointed him [Mr. Rushing] as the Vice President of Quality, recognizing his exceptional qualifications and experience in pharmaceutical quality validation and cGMP compliance,” noted Mr. Night.

Mr. Rushing’s appointment follows the recent appointment of Dr. Krishna Bhat (MD, Ph.D., FACC as the company’s new Chief Medical Advisor and Dr. David Aguilar (Ph.D.) as the new Chief Operating Officer (“COO”) (https://ibn.fm/ZFLRS). These are all in a bid to strengthen the company’s governing team while propping it for success as it expands on the most ambitious phase of the company’s progression.

SOHM also recently signed a letter of intent (“LOI”) to acquire A Binding Based Integrating Enzyme (“ABBIE”) stem cell disruptive technology and patents from CGA Intellectual Holdings Inc. This would allow it to create novel products and solutions in the regenerative medicine and cosmeceutical industries, a useful asset in SOHM’s growing portfolio (https://ibn.fm/4o6Fk). The three appointments will be integral in leveraging this product, bringing it to market, and even utilizing it to create novel products and solutions for customers.

SOHM envisions a future where it evolves into a prominent global corporation with corresponding market reach, while maintaining its fundamental core values. So far, it is on track to extend its export portfolio to 11 countries, a milestone that reflects its growing expertise. These recent appointments build on the success and the momentum gained so far, and management is increasingly confident about anticipated developments and opportunities.

For more information, visit the company’s website at www.SOHM.com.

NOTE TO INVESTORS: The latest news and updates relating to SHMN are available in the company’s newsroom at https://ibn.fm/SHMN

• The BRAIN Foundation’s Synchrony Symposia is the first and only international symposium on translational research for Autism Spectrum Disorder (“ASD”)
• PaxMedica Chairman and CEO Howard Weisman says that participating at the symposium is pivotal in advancing and fostering autism research
• As a Gold Sponsor, PaxMedica will have purview to the symposium’s interdisciplinary discussions, insights, and research presentations, clinical roundtables, mentor-mentee sessions, and more

PaxMedica (NASDAQ: PXMD), a clinical-stage biopharmaceutical company focused on the development of novel anti-purinergic therapies (“APTs”) for the treatment of Autism Spectrum Disorder (“ASD”) and other serious conditions with intractable neurologic symptoms, recently announced its Gold Sponsorship of The BRAIN Foundation’s esteemed Synchrony Symposia 2023. The BRAIN Foundation supports translational research that will lead to the development of FDA-approved treatments and an improved standard of care for co-morbidities in individuals with ASD.

The Synchrony Symposia is the first and only international symposium on translational research for ASD – bringing together academia, biotech, pharmaceutical companies, venture partners, and more to catalyze scientific research that can improve health and the quality of life for people with autism and other neurodevelopmental disorders. The interdisciplinary forum brings together the brightest minds to collaborate and innovate, featuring CME-accredited presentations from leading scientists and clinicians.

“We are honored to support The BRAIN Foundation’s Synchrony Symposia. This symposium plays a pivotal role in advancing scientific knowledge and fostering collaboration among experts in the field of autism research,” said Howard Weisman, Chairman and CEO of PaxMedica (https://ibn.fm/iQCel). “PaxMedica is deeply committed to improving the lives of individuals with autism and their families, and we are excited to contribute to this vital initiative.”

Through its Gold Sponsorship, PaxMedica demonstrates its dedication to supporting research that can lead to advancements in understanding and treating ASD and other neurodevelopmental disorders. One of the company’s primary points of focus is developing and testing its lead program, PAX-101, an intravenous formulation of suramin for the treatment of ASD and advancing clinical understanding of using it for other disorders such as Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS).

The company’s robust pipeline of products, including PAX-101, may help eliminate, reduce, or modulate some of the more troublesome aspects of ASD. Both lead programs, PAX-101 and PAX-102, utilize the company’s proprietary source of suramin sodium, a broadly acting anti-purinergic therapy known for over 100 years. Suramin was originally used for treating Human African Trypanosomiasis (“HAT”), or African Sleeping Sickness, which is currently in the company’s plan for raising funding for its ASD research and development efforts.

PaxMedica plans to use previously reported data for suramin to persuade the FDA to allow licensing to the company to use and subsequently license suramin to other pharmaceutical companies to treat rare occurrences of HAT in the United States. From those proceeds, the company will pursue its use of suramin for ASD research.

According to Fortune Business Insights, the global autism spectrum disorder therapeutics market was valued at $1.93 billion in 2022 and is projected to grow from $2.01 billion in 2023 at a CAGR of 7.9% from 2023 to 2030. By 2030, the market is expected to reach $3.42 billion (https://ibn.fm/0wQU9).

PaxMedica’s commitment to this cause aligns seamlessly with the Synchrony Symposium’s mission. As the only publicly traded U.S. company primarily focused on autism, PaxMedica is dedicated to developing groundbreaking therapies that address the unmet medical needs of individuals with ASD. The symposium offers a platform for attendees to engage in interdisciplinary discussions, gain insight, and participate in research presentations, clinical roundtables, mentor-mentee sessions, and more.

For more information, visit the company’s website at www.PaxMedica.com.

NOTE TO INVESTORS: The latest news and updates relating to PXMD are available in the company’s newsroom at https://ibn.fm/PXMD

• In line with recent emphasis on the growing importance of nanotechnology in the US, Clene Nanomedicine innovated its investigational drug, CNM-Au8(R), using nanotechnology for the treatment of neurodegenerative disease
• Clene’s nanotechnological approach was recently recognized by the NINDS of NIH with a substantial grant to conduct an Expanded Access Protocol in ALS with CNM-Au8(R)
• Clene aims to file a New Drug Application for CNM-Au8(R) for ALS indications in the first half of 2024

October 2023 has turned into a month for the celebration of nanotechnology. On Wednesday, Oct. 4, 2023, three U.S.-based scientists, Moungi Bawendi, Louis Brus, and Aleksey Ekimov, were awarded the 2023 Nobel Prize in Chemistry for their discovery and synthesis of tiny clusters of atoms known as quantum dots, which are widely used today in applications as diverse as digital flat screens to surgery. On Friday, Oct. 6, the White House Office of Science and Technology Policy tweeted, “Happy #NationalNanoDay! #Nanotechnology is at the heart of many recent and emerging technologies, such as #NobelPrize winning #QuantumDots, higher energy density #batteries, hardware for #AI, and #QuantumComputers. What will nanotechnology enable in the future?”  Clene Nanomedicine believes that its lead asset, CNM-Au8(R), holds one such key to the future: the future of medicines to treat neurodegenerative disease.

Clene (NASDAQ: CLNN) is a biopharmaceutical company that aims to revolutionize the treatment of neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”), Parkinson’s Disease, and multiple sclerosis (“MS”). CNM-Au8 is manufactured by Clene using patented nanotechnology that results in an investigational drug with catalytic activity that targets mitochondrial health to improve neuronal function and survival. By increasing energy production and utilization inside cells, CNM-Au8 has been shown to enable neuroprotection and remyelination in multiple independent preclinical studies.

CNM-Au8 has now been investigated in two independent, Phase 2, randomized, double-blind, placebo-controlled,clinical trials, RESCUE-ALS, conducted at sites in Australia, and the Healey Platform Trial, led by Massachusetts General Hospital and conducted at clinical sites across the US in conjunction with the NEALS Consortium. In RESCUE-ALS, the survival difference for 30mg CNM-Au8 ALS-treated participants exhibited a 19.3-month survival rate versus the placebo. During the double-blind portion of the HEALEY ALS Platform Trial, participants on the 30mg CNM-Au8 dose demonstrated a 98% decreased risk of death over the Regimen’s placebo group, a benefit that is sustained during the trial’s open label extension. These promising results were used to support a grant application to NINDS/NIH to support an Expanded Access Protocol for CNM-Au8 in ALS, which was subsequently awarded to Clene in collaboration with Columbia University and Synapticure, and announced on Oct. 5, 2023. Clene plans to file a New Drug Application for CNM-Au8 for ALS indications with the FDA in the first half of 2024. As of January 2023, Clene has over 150 issued patents worldwide with approximately 20 more patents pending, on top of trade secrets.

The global ALS treatment market was valued at $647.9 million in 2020 and is expected to reach $885.5 million, growing at a CAGR of 5.8%. The market is driven by the prevalence of the disease among geriatric patients. Still, this neurodegenerative disease affects patients at different rates and presents with varying symptoms, making it difficult to control and diagnose (https://ibn.fm/Ij5Q9).

CNM-Au8 has accumulated over 500 years of exposure in patients with ALS, MS, and Parkinson’s Disease with no serious adverse event attributed to the drug. CNM-Au8 is federally registered and trademarked to Clene Inc.

For more information, visit the company’s website at www.Clene.com.

NOTE TO INVESTORS: The latest news and updates relating to CLNN are available in the company’s newsroom at https://ibn.fm/CLNN

• Digital engagement innovator Electronic Servitor Publication Network is devoted to using advanced automated, interactive technological solutions to help clients build their businesses and retain customers through powerful and cost-effective customer engagement
• The global customer engagement solutions market is expected to grow at a CAGR of 10.8 percent between 2022 and 2027, with a value of $32.2 billion, according to Customer Engagement Solutions Market analysis
• Electronic Servitor Publication Network bases its growth-as-a-service managed offering on its proprietary Digital Engagement Engine(TM) technology, which provides customer-tailored content, data analysis, niche identification, and prompt responsiveness

The trending nature of advanced conversational intelligence has granted it a growing wave of media gravitas in recent months, including a September report by The Intelligence. The report noted that communications technology mega cap company Apple is investing “millions of dollars a day” to further develop conversational intelligence features in its products such as the iPhone and its Siri voice assistant (https://ibn.fm/lH08j).

Robotics and Automation News noted the importance of using such technologies to improve customer interactions, including order service and upselling, in a recent report on the technology’s B2B potential. The report notes that the use of smart chatbots and virtual assistants in customer experience (“CX”) settings seems futuristic but is already being employed as a game-changing tool by companies to elevate their virtual help desks, add-on feature delivery, order tracking, experience personalization, collection of feedback, human resources training, and billing in prompt fashion (https://ibn.fm/YXcXb).

Digital engagement innovator Electronic Servitor Publication Network (OTCQB: XESP) is helping to drive B2B growth through smart digital activation and engagement solutions that feature its proprietary Digital Engagement Engine(TM), producing intelligent interaction management, dynamic content, and a logic-driven workflow.

The Minnesota-based company is focused on helping clients develop real connections with their target markets. While the Digital Engagement Engine is a powerful tool for any company’s platform, its purpose is to empower companies to control customer interaction content while sustaining revenue streams and building new customer relationships.

Using a combination of automation, unique data management, and a modern workflow built on a microservices architecture, Electronic Servitor Publication Network provides a managed service that includes analysis of customer interaction productivity without the need for additional staffing and the associated costs. Electronic Servitor Publication Network also ensures the proper integration of its technology with their clients’ infrastructure.

As an effective manager of smart, automated customer interactions, the company promotes meaningful communication between its clients and their audiences rather than a customer-facing monologue that overlooks the potential benefits of customer input.

The result is a streamlined, efficient model for promoting and growing business while retaining customers’ interest in the products and services that brought them in the door in the first place. Analysts at Customer Engagement Solutions Market predict global customer engagement solutions will grow at a CAGR of 10.8 percent between 2022 and 2027, achieving $32.2 billion in revenues (https://ibn.fm/LHjJm).

For more information, visit the company’s website at www.XESPN.com.

NOTE TO INVESTORS: The latest news and updates relating to XESP are available in the company’s newsroom at https://ibn.fm/XESP

• Lexaria recently announced its intention to launch new human and animal studies exploring its patented DehydraTECH(TM) technology on GLP-1 drugs for the potential treatment of diabetes
• The studies will build on what Lexaria has achieved so far since it started its diabetes-related studies in 2022
• Its DehydraTECH-CBD demonstrated an almost three-fold improvement in drug delivery into the blood in its DIAB-A22-1 diabetes study compared to the DehydraTECH-CBD formulation used in its HYPER-H21-4 hypertension study
• These studies follow Lexaria’s announcement of its intention to study weight loss and diabetes control in a human population using DehydraTECH

Lexaria Bioscience (NASDAQ: LEXX), a global innovator in drug delivery platforms, just announced its intention to launch new human and animal studies that will explore its patented DehydraTECH(TM) technology on glucagon-like peptide-1 (“GLP-1”) drugs for improved bioavailability, cost-effectiveness, tolerability, weight loss potential, management of diabetes and other health conditions. Regarded as a significant expansion for Lexaria, these studies will build on what the company has achieved so far with its DehydraTECH-processed CBD while examining the technology’s impact on GLP-1 drugs (https://ibn.fm/r18NV).

The U.S. Food and Drug Administration (“FDA”) recently approved GLP-1 drugs for type 2 diabetes and weight loss management following their demonstration of an average loss of 15% of body weight across 667 individuals in a 68-week-long study. The drug has also demonstrated that some patients experience reduced cravings for alcohol, nicotine, and opioids while taking the drugs, with other trials showing the reduced build-up of proteins amyloid and tau in the brain, both thought to be partly responsible for Alzheimer’s.

Despite their overall potential, GLP-1 drugs have many side effects, ranging from mild ones, such as nausea and vomiting, to more serious ones, such as reduced bone density and muscle loss. Some of the more severe side effects have been reported when the drugs are taken in oral form, which has prompted researchers and medical practitioners to treat patients with lower oral doses. Given the overall nature of GLP-1 drugs to have low oral bioavailability, Lexaria, through its DehydraTECH technology, looks to address that, ultimately improving the drug’s pharmacokinetic (“PK”) performance.

In the recently completed DIAB-A22-1 diabetes study, Lexaria demonstrated an almost three-fold improvement in drug delivery into the blood compared to the DehydraTECH-CBD formulation used in its HYPER-H21-4 hypertension study. With such results in this and five other human clinical studies, Lexaria has proven severally that its technology can significantly improve the PK performance of many orally administered drugs into the bloodstream. Its applications have ranged from cannabinoids, estradiol, PDE-5 Inhibitors, and certain antiviral drugs. The company is optimistic about the technology’s application, GLP-1, and its potential to improve its bioavailability.

The animal and human clinical studies on GLP-1 will be a logical progression to Lexaria’s efforts to explore DehydraTECH in the potential treatment of diabetes, which kicked off in 2022. In its pre-clinical study DIAB-A22-1, DehydraTECH-CBD has yielded a 19.9% lowered blood glucose level, a 7% lowered overall body weight sustained over eight weeks, increased locomotor activity, lowered triglyceride levels by more than 25%, and lowered blood urea nitrogen levels by 27.9%. Given its intention to study weight loss and diabetes control in a human population using DehydraTECH, as announced on August 2, 2023, the GLP-1 studies come at the opportune time, facilitating this specific objective.

Program design for the GLP-1 study has already commenced, and initial study work is set to begin as soon as possible. This ambitious step affirms Lexaria’s commitment to creating shareholder value and advancing its technology to become a leader in its segment.

For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LEXX are available in the company’s newsroom at https://ibn.fm/LEXX

• Appia recently entered into a definitive agreement to acquire up to a 70% interest in the 17,551.07-hectare PCH Project located in the State of Goiás, Brazil
• The company completed a due diligence program, with the initial results confirming widespread REE enrichment across the property
• Total rare earth element (“REE”) grades in numerous auger holes drilled at Target 4 ranged from 274 parts per million (“ppm”) to 16,648 ppm (1.66%), with an average of 1,291 ppm total REE, the results showed
• The PCH Project has a relatively higher content of heavy REE (“HREE”) in the deposit than Serra Verde, a large ionic-clay REE deposit and mine currently under construction in northern Goiás State
• Appia has since embarked on comprehensive exploration activities to uncover the potential of its highly promising deposit

Appia Rare Earths & Uranium (CSE: API) (OTCQX: APAAF), a mineral exploration with multiple rare earths and uranium projects in mining-friendly jurisdictions, including Goiás State, Brazil and Saskatchewan and Ontario, Canada, took a “significant step in cementing itself among the upper tier of critical mineral explorers,” according to company President Stephen Burega, when it entered into a definitive agreement to acquire up to a 70% interest in the PCH Project (https://ibn.fm/cnyNm).

Located in the Tocantins Structural Province of the Brasilia Fold Belt, Goiás State, Brazil, the 17,551.07-hectare PCH Project is one of the few major ionic clay projects in the Western world and one of the relatively few ionic clay REE deposits found outside China. Ionic clays can be mined with low-cost open-pit mining technologies and processed using simple technologies, according to Burega (https://ibn.fm/ZX1UL), suggesting that the PCH Project will require low capital and operational expenditures.

The viability of the open pit mining system is supported by the fact that the project shows ionic clay development with elevated rare earth element (“REE”) values immediately below the surface and extending down to a depth of more than 15 meters, based on assay results obtained from the vendor of the high potential property (original assays).

Still, the company set out to confirm whether the original assay results represented the true composition and quality of the property, commencing a due diligence program in April this year. As part of the due diligence program, Appia completed 110 duplicate samples from twin augur holes staggered across Target 4 of the property and found comparable results to the original assays. The company also collected 17 samples from trenches and 76 samples from diamond drill holes, with the results comparable to the original results.

These initial results confirmed widespread REE mineralization in ionic clays deposited after weathering of alkaline granitic source rocks as well as in-situ REE enrichment linked to the area’s underlying granite complex and a carbonatite intrusion extending to depths of more than 100 meters (https://ibn.fm/5ak7t).

“Mineralization is widespread across the property, with the most advanced target being a 2 km wide zone in the southwestern corner of the tenements known as Target 4,” commented Don Hains, an expert in industrial minerals and a senior consulting geologist. “The exploration work by the vendor showed REE enrichment in the soils to depths of 8 to 26 m with the majority in the upper 8-10 meters. Total REE grades in numerous auger holes drilled at Target 4 ranged from 274 parts per million (“ppm”) to 16,648 ppm (1.66%), with an average of 1,291 ppm total REE and, importantly, the valuable rare earths used in magnet applications (Pr, Nd, Tb, and Dy) + Y accounted for approximately 14% of total rare earths, with a maximum of 28.4%.”

The initial results also showed that heavy REE (“HREE”) accounted for 13.93% of the total rare earths or 145 ppm. The company compared its results with data from the Serra Verde Project, a large ionic-clay REE deposit and mine currently at advanced stages of construction in the northern part of the Goiás State, noting that the PCH Project has a relatively higher content of HREE in the deposit than Serra Verde despite having lower total average REE values. “The Serra Verde project currently under construction in northern Goiás State has total average REE values of 2,138 ppm (0.2138%) but HREE values of only 155 ppm, or 7.26% of total rare earths,” explained Hains.

Encouraged, the company embarked on comprehensive exploration activities to uncover the potential of its highly promising deposit. So far, Appia’s exploration team has employed a strategic combination of cutting-edge LiDAR surveying, extensive auger sampling, and Reverse Circulation (“RC”) drilling. The company intends to use the data collected from these drill and survey programs to develop an initial mineral resource estimate (“MRE”) on Target 4 (https://ibn.fm/AxXI3).

For more information, visit the company’s website at www.AppiaREU.com.

NOTE TO INVESTORS: The latest news and updates relating to APAAF are available in the company’s newsroom at https://ibn.fm/APAAF

Serious investors — and anyone concerned with protecting and building wealth in volatile times — invited to attend the New Orleans Investment Conference to be held in New Orleans, November 1-4, 2023.

With a rich legacy spanning almost 50 years, the New Orleans Investment Conference has been acclaimed as “The Greatest Investment Show on Earth” by Money Magazine. Held in the heart of New Orleans, the 2023 Conference is set to present a dream team of world-class experts on geopolitics, macroeconomics and every asset class to hundreds of savvy investors.

The 2023 Conference will feature enlightening presentations from leading experts such as Konstantin Kisin, Matt Taibbi, Jim Rickards, Danielle DiMartino Booth, Lyn Alden, George Gammon, Rick Rule, Dominic Frisby, Brent Johnson, Dave Collum, Peter Boockvar, James Stack, Peter Schiff, Jim Iuorio, Tavi Costa, Adrian Day, Adam Taggart, The Real Estate Guys, Gwen Preston, Brent Cook, Brien Lundin, and many more. Early bird registration is still open, offering significant savings for those who secure their spots early.

To learn more, please visit https://ibn.fm/ISvQC